The Alternative Investment Market (AIM) of the London Stock Exchange has historically served as a critical incubator for high-growth healthcare technology and medical device companies, providing a unique environment where innovative small-to-mid-cap entities can access public capital while benefiting from a more flexible regulatory regime than the Main Market. As of March 2026, the sector is characterised by a profound transition. The intersection of the United Kingdom gover